CA
MYGN icon

CastleArk Alternatives’s Myriad Genetics MYGN Stock Holding History

CastleArk Alternatives’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-292,850
Closed -$9.46M – 187
2021
Q3 		$9.46M Buy
+292,850
New +$9.72M 0.36% 79

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CastleArk Alternatives's MYGN Position: Q4 2021 in Review

CastleArk Alternatives sold out of Myriad Genetics (MYGN) in Q4 2021, closing a stake of 292,850 shares — an estimated $9.46M sold.

CastleArk Alternatives first reported a position in MYGN in Q3 2021 and held it in 1 quarter. The position peaked at $9.46M in Q3 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2021.

  • CastleArk Alternatives reported no remaining Myriad Genetics position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 292,850 Myriad Genetics shares in Q4 2021, an estimated $9.46M.
  • CastleArk Alternatives first reported a position in Myriad Genetics in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Myriad Genetics position peaked at $9.46M in Q3 2021.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.